

Policy Statement	Trelegy inhaler (fluticasone, vilanterol & umeclidinium) for the treatment of Chronic Obstructive Pulmonary Disease (COPD)
Policy Number	PCN 354 - 2018
Date of Issue	September - 2018
Review Date:	September - 2021 <i>(Unless new published evidence becomes available before this date OR there is new published national guidance e.g. NICE)</i>
<p>Recommendations: The Prescribing Clinical Network recommends Trelegy inhaler for the treatment of Chronic Obstructive Pulmonary Disease (COPD) and it will be considered GREEN on the traffic light system as follows:</p> <p>1st line triple therapy combination inhaler:</p> <ul style="list-style-type: none"> • Trimbow inhaler with a spacer (improved lung deposition) <p>2nd line triple therapy combination inhaler:</p> <ul style="list-style-type: none"> • Trelegy inhaler <p>Triple therapy combination inhalers are recommended as a treatment option in COPD for the following patients:</p> <ul style="list-style-type: none"> • On a LABA/LAMA combination inhaler who have an FEV1 <50% predicted and ≥2 exacerbations per year or ≥1 exacerbation leading to hospital admission, i.e. patients at GOLD D classification. <p>OR</p> <ul style="list-style-type: none"> • Currently stabilised on triple therapy (ICS/LABA) & LAMA) in separate devices AND there has been a review of the dose of steroids and a 'step down' in treatment is not appropriate <p>Patients should be assessed for benefit of triple therapy and if after 6 months of treatment the patient has continued exacerbations, consider referral to a specialist respiratory team</p>	
<p>Key Considerations:</p> <ul style="list-style-type: none"> • Global initiative for chronic obstruction lung disease (GOLD) recommendations https://goldcopd.org/wp-content/uploads/2017/11/GOLD-2018-v6.0-FINAL-revised-20-Nov_WMS.pdf • Chronic obstructive pulmonary disease: beclometasone, formoterol and glycopyrronium (Trimbow) https://www.nice.org.uk/advice/es17/resources/chronic-obstructive-pulmonary-disease-beclometasone-formoterol-and-glycopyrronium-trimbow-pdf-1158120380869 • Chronic obstructive pulmonary disease: fluticasone furoate, umeclidinium and vilanterol (Trelegy) https://www.nice.org.uk/advice/es18/resources/chronic-obstructive-pulmonary-disease-fluticasone-furoate-umeclidinium-and-vilanterol-trelegy-pdf-1158122061781 	
Date taken to Prescribing Clinical Network	5 th September 2018
Agreed by PCN members	

Surrey (East Surrey CCG, Guildford & Waverley CCG, North West Surrey CCG, Surrey Downs CCG & Surrey Heath CCG), Crawley CCG and Horsham & Mid-Sussex CC